artificial intelligence

The deal is aimed at providing technologies, products, and services that will improve the standardization of pathology labs and accelerate accurate diagnoses.

Proscia said that the collaboration will focus initially on prostate cancer and then expand to several cancer subspecialties.

Of the 28 companies in the index, 16 companies' share prices increased while the share values of 12 declined month over month. 

The group aims to develop a transcriptomic and epigenetic biomarker assay for early detection and relapse monitoring in colorectal cancer patients. 

GTC will sequence samples and help with technical and clinical validation, while C2i will perform AI-based analysis of the data, recruit samples, and perform other clinical trial activities.

While it was developed and validated for brain tumor classification, the workflow could be extended to other cancers where intraoperative histology is valuable.

The firm said that the new financing will help it accelerate commercial initiatives in the US, Europe, Brazil, and Canada.

The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.

The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.